Should I ignore the falling GlaxoSmithKline share price and pocket its 6% yield anyway?

The falling GlaxoSmithKline share price makes today’s valuation look attractive, and the generous 5.86% yield is also tempting. So what’s my problem?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many people assume the pandemic would be positive for pharmaceutical stocks but the falling GlaxoSmithKline (LSE: GSK) share price tells a different story. It has now trading 25% lower than a year ago.

While you should treat past performance with caution, this is both surprising and disappointing. It’s not a one-off fall either. The GlaxoSmithKline share price has gone precisely nowhere, measured over five years. Despite that, the FTSE 100 pharma giant remains one of the UK’s most popular stocks, lauded for its thumping dividend yield. Should I buy Glaxo for the income, or shun it after the share price slump?

Right now, Glaxo yields 5.86%. That is a terrific level of income, especially today. You cannot directly compare a dividend yield to the interest rate on cash, as the latter is pretty much guaranteed. However, Glaxo’s yield looks tempting at a time when the average easy access account pays just 0.18%.

I’m checking out the GlaxoSmithKline share price

Yields are funny things, though. They are calculated by dividing a company’s dividend per share, against its share price. Right now, Glaxo’s dividend per share stands at 80p, while its share price is 1,365p. So 80/1,356 = 5.86.

When a company’s share price is falling, as seen with GlaxoSmithKline, the yield rises (all things being equal). So a high yield is often the sign of a struggling company, rather than a thriving one.

Glaxo certainly faces challenges right now, as Credit Suisse has just noted. It highlighted poor R&D productivity, and said management needs to invest more in the drugs pipeline. 

Another worry is that its shingles vaccine, Shingrix, cannot be taken alongside the Covid-19 vaccine. This will hit a key source of revenue growth, especially if populations need to be vaccinated year after year.

Here’s another reason why the GlaxoSmithKline share price is under pressure. CEO Emma Walmsley is planning to spin off its consumer joint venture with Pfizer. Credit Suisse has warned this could threaten shareholder payouts, as Glaxo’s biopharma operation “would need to pay out 84% of earnings to maintain its 80p dividend”.

The GlaxoSmithKline share price is not falling by accident. FTSE 100 rival AstraZeneca‘s share price has scarcely dipped over the last 12 months, and is up 80% measured over five years. 

Still a top FTSE 100 dividend stock

That said, many investors like buying companies that have suffered short-term setbacks, because they are often available at bargain prices. Currently, the GlaxoSmithKline share price trades at just 11 times earnings, which is one of the lowest valuations I can remember.

Earnings growth has been slowing, though. In 2016, earnings grew 35% but this has since slowed to 9%, 7%, and 4% a year. The trajectory is clear.

I would never buy the GlaxoSmithKline share price with a short-term view, or any stock for that matter. I  look to hold it for at least five years, and ideally 10 or 20 years. Over that time scale, today’s worries will seem like a blip. But today’s buyers will continue to benefit from today’s low entry price.

I find myself tempted by the falling GlaxoSmithKline share price. Even more so by its yield. Even if it cuts its dividend, I should still get a generous level of income.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

I’d buy 1,784 shares of this FTSE 100 stock to target £350 of monthly passive income

Muhammad Cheema takes a look at how British American Tobacco shares, with a dividend yield of 10.1%, can generate a…

Read more »

White female supervisor working at an oil rig
Investing Articles

1 ex-FTSE 100 stock that I think will get promoted soon

Jon Smith flags up an energy stock that used to be in the FTSE 100 and currently has strong momentum…

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »